News | June 20, 2012

SNM 2012 Image of the Year

Peptide receptor alpha therapy is well tolerated and has therapeutic effect

June 20, 2012 — The Society of Nuclear Medicine’s (SNM) 2012 Image of the Year illustrates the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that do not respond to beta therapy. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNM’s 2012 Annual Meeting in Miami Beach, Fla.

Each year, SNM chooses an image that exemplifies the most cutting-edge nuclear medicine or molecular imaging research today and that demonstrates the ability of molecular imaging to detect and diagnose disease and help select the most appropriate therapy. “The images illustrating the effectiveness of Bi-213-DOTATOC for GEP-NETs show the remarkable results that can be achieved in a clinical setting,” said Peter Herscovitch, M.D., chair of SNM’s Scientific Program Committee. “This opens up a new door for those patients whose GEP-NETs do not respond to more standard radiotherapy.”

GEP-NETs are rare, slow-growing tumors that develop in the digestive system and are distributed throughout the body. They fall into two main categories—carcinoid tumors and pancreatic endocrine tumors—and are often resistant to standard chemotherapy. The National Cancer Institute estimates about 1,000 new cases of pancreatic neuroendocrine tumors per year in the United States.

In this study, a Bi-213-DOTATOC was synthesized using a microwave-assisted labeling protocol. Twenty-one patients who had previously shown a resistance to treatment with Y-90 or Lu-177-DOTATOC were treated with escalating doses of the peptide receptor alpha-therapy—from 1-10 GBq up to 21 GBq. Researchers assessed response with Ga-68-DOTATOC PET/CT (positron emission tomography/computed tomography), contrast-enhanced sonography, magnetic resonance imaging, digital subtraction angiography and tumor markers. In addition, markers for hematologic, kidney and endocrine toxicity were monitored during and after treatment.

The labeling protocol for Bi-213-DOTATOC provided reliable doses of the treatment at a clinical level. Patients tolerated the increasing doses well, and there was no acute kidney, endocrine or hematologic toxicity. Shrinkage of primary tumors as well as liver and bone metastases was observed.

Alfred Morgenstern, Ph.D., project leader of the Alpha-Immunotherapy Project at the European Commission, Joint Research Centre, Institute for Transuranium Elements in Karlsruhe, Germany, and lead author of the study, “Synthesis of Bi-213-DOTATOC for peptide receptor alpha-therapy of GEP-NET patients refractory to beta therapy,” noted: “The images illustrate the potential of Ga-68-DOTATOC PET and PET/CT to assess the therapeutic effects we can achieve in multiresistant neuroendocrine tumors with Bi-213-DOTATOC. It’s very exciting to see that peptide receptor alpha therapy with Bi-213-DOTATOC is offering a promising novel therapeutic option for patients refractory to existing therapies.”

For more information: www.snm.org

Related Content

PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
Overlay Init